BTAI RSI Chart
Last 7 days
4.9%
Last 30 days
-19.9%
Last 90 days
-7.3%
Trailing 12 Months
-87.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 626.3K | 877.5K | 1.1M | 1.4M |
2022 | 0 | 0 | 0 | 375.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 14, 2023 | yocca frank | acquired | - | - | 521 | chief scientific officer |
Dec 14, 2023 | steinhart richard i | acquired | - | - | 521 | chief financial officer |
Dec 14, 2023 | o'neill vincent | acquired | - | - | 521 | chief medical officer |
Dec 14, 2023 | mehta vimal | acquired | - | - | 2,609 | ceo and president |
Dec 14, 2023 | rodriguez javier | acquired | - | - | 521 | see remarks |
Sep 14, 2023 | yocca frank | acquired | - | - | 521 | chief scientific officer |
Sep 14, 2023 | steinhart richard i | acquired | - | - | 521 | chief financial officer |
Sep 14, 2023 | o'neill vincent | acquired | - | - | 521 | chief medical officer |
Sep 14, 2023 | mehta vimal | acquired | - | - | 2,610 | ceo and president |
Sep 14, 2023 | rodriguez javier | acquired | - | - | 521 | see remarks |
Which funds bought or sold BTAI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 2,764 | 2,764 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -10.74 | 125,974 | 3,213,920 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | reduced | -71.1 | -222,891 | 113,280 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.41 | 4,129 | 29,745 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 176,000 | 176,000 | 0.01% |
Feb 15, 2024 | BARCLAYS PLC | added | 264 | 64,000 | 82,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | reduced | -77.5 | -24,938 | 8,913 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | reduced | -78.09 | -266,861 | 91,577 | -% |
Feb 15, 2024 | Virtus ETF Advisers LLC | sold off | -100 | -11,754 | - | -% |
Feb 14, 2024 | MARSHALL WACE, LLP | sold off | -100 | -71,359 | - | -% |
Unveiling Bioxcel Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bioxcel Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Bioxcel Therapeutics Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 |
Revenue | 10.3% | 376 | 341 | 457 | 206 | 172 | 137 |
Costs and Expenses | -58.4% | 20,250 | 48,638 | 52,871 | 51,404 | 53,129 | 39,127 |
S&GA Expenses | -60.6% | 9,603 | 24,344 | 25,872 | 23,595 | 20,534 | 17,054 |
R&D Expenses | -49.4% | 9,934 | 19,619 | 26,973 | 27,800 | 32,586 | 22,062 |
Interest Expenses | 5.6% | 3,436 | 3,252 | 3,259 | 3,367 | 2,920 | 3,700 |
Net Income | 55.9% | -22,256 | -50,486 | -53,515 | -52,796 | -54,808 | -41,805 |
Net Income Margin | 30.8% | -129.75* | -187.47* | -231.25* | -298.73* | -442.02* | - |
Free Cashflow | 28.5% | -26,863 | -37,584 | -38,206 | -52,353 | -38,639 | -31,186 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -26.6% | 74.00 | 100 | 140 | 180 | 206 | 245 | 248 | 211 | 239 | 261 | 281 | 200 | 220 | 239 | 70.00 | 86.00 | 36.00 | 44.00 | 34.00 | 40.00 | 44.00 |
Current Assets | -26.9% | 72.00 | 99.00 | 138 | 177 | 203 | 242 | 245 | 208 | 237 | 257 | 277 | 197 | 217 | 236 | 68.00 | 84.00 | 34.00 | 41.00 | 32.00 | 38.00 | 43.00 |
Cash Equivalents | -27.5% | 65.00 | 90.00 | 128 | 166 | 194 | 232 | 233 | 200 | 233 | 253 | 273 | 194 | 213 | 233 | 65.00 | 80.00 | 32.00 | 40.00 | 30.00 | 36.00 | 43.00 |
Inventory | -1.3% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -9.0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | -7.7% | 130 | 141 | 134 | 127 | 129 | 118 | 84.00 | 17.00 | 18.00 | 16.00 | 14.00 | 14.00 | 13.00 | 18.00 | 17.00 | 13.00 | 9.00 | 9.00 | 9.00 | 8.00 | 5.00 |
Current Liabilities | -30.8% | 27.00 | 39.00 | 35.00 | 29.00 | 33.00 | 23.00 | 20.00 | 16.00 | 17.00 | 15.00 | 12.00 | 12.00 | 12.00 | 16.00 | 16.00 | 12.00 | 8.00 | 8.00 | 8.00 | 7.00 | 5.00 |
Long Term Debt | -100.0% | - | 99.00 | 97.00 | 95.00 | 93.00 | 92.00 | 61.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 1.5% | 101 | 99.00 | 97.00 | 95.00 | 93.00 | 92.00 | 61.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -Infinity% | -56.51 | - | 6.00 | 53.00 | 77.00 | 127 | 164 | 194 | 222 | 246 | 267 | 187 | 207 | 221 | 53.00 | 73.00 | 27.00 | 34.00 | 25.00 | 32.00 | 39.00 |
Retained Earnings | -3.9% | -590 | -568 | -517 | -464 | -411 | -356 | -314 | -277 | -245 | -219 | -192 | -165 | -138 | -117 | -93.02 | -71.60 | -56.69 | -48.41 | -39.40 | -30.92 | -23.72 |
Additional Paid-In Capital | 1.2% | 534 | 528 | 524 | 517 | 488 | 484 | 479 | 471 | 467 | 465 | 460 | 352 | 346 | 339 | 146 | 144 | 84.00 | 83.00 | 65.00 | 63.00 | 63.00 |
Shares Outstanding | 2.2% | 30.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 26.00 | 25.00 | 25.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 251 | - | - | - | 551 | - | - | - | 565 | - | - | - | 63.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 28.5% | -26,863 | -37,584 | -38,206 | -52,353 | -38,639 | -31,186 | -33,103 | -32,413 | -19,932 | -20,199 | -22,382 | -19,640 | -20,272 | -19,101 | -14,820 | -12,157 | -7,919 | -7,485 | -6,027 | -5,670 | -4,341 |
Share Based Compensation | -10.3% | 3,599 | 4,014 | 6,124 | 4,877 | 4,547 | 4,483 | 4,482 | 3,825 | 2,236 | 4,885 | 6,769 | 5,565 | 6,611 | 5,268 | 1,956 | 776 | 654 | 776 | 1,030 | 682 | 133 |
Cashflow From Investing | - | - | - | - | - | - | - | -19.00 | -120 | -12.00 | -17.00 | -100 | -316 | -270 | 5.00 | -35.00 | -16.00 | -2.00 | -43.00 | -225 | -600 | - |
Cashflow From Financing | - | 2,123 | - | 250 | 24,149 | 50.00 | 30,048 | - | - | - | 71.00 | 101,524 | 852 | 233 | 187,029 | 271 | 59,826 | 95.00 | 17,815 | -79.00 | 1.00 | -58.00 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9,024 | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | ||
Product revenue, net | $ 1,380 | $ 375 |
Operating expenses | ||
Cost of goods sold | 1,260 | 20 |
Research and development | 84,326 | 91,239 |
Selling, general and administrative | 83,413 | 68,761 |
Restructuring costs | 4,163 | |
Total operating expenses | 173,162 | 160,020 |
Loss from operations | (171,782) | (159,645) |
Other expense (income) | ||
Interest expense | 13,314 | 8,213 |
Interest income | (5,649) | (2,528) |
Other (income) expense, net | (394) | 427 |
Net loss | $ (179,053) | $ (165,757) |
Basic net loss per share attributable to common stockholders (in dollars per share) | $ (6.15) | $ (5.92) |
Diluted net loss per share attributable to common stockholders (in dollars per share) | $ (6.15) | $ (5.92) |
Weighted average shares outstanding - basic (in shares) | 29,129 | 28,015 |
Weighted average shares outstanding - diluted (in shares) | 29,129 | 28,015 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 65,221 | $ 193,725 |
Accounts receivable, net | 71 | 248 |
Inventory | 1,991 | 1,985 |
Prepaid expenses | 2,782 | 3,067 |
Other current assets | 2,078 | 3,843 |
Total current assets | 72,143 | 202,868 |
Property and equipment, net | 784 | 1,084 |
Operating lease right-of-use assets | 688 | 976 |
Other assets | 87 | 925 |
Total assets | 73,702 | 205,853 |
Current liabilities | ||
Accounts payable | 13,654 | 10,228 |
Accrued expenses | 12,424 | 18,669 |
Accrued interest | 736 | 3,175 |
Total current liabilities | 27,267 | 32,898 |
Long-term portion of operating lease liabilities | 440 | 786 |
Derivative liabilities | 1,905 | 2,343 |
Long-term debt | 100,598 | 93,051 |
Total liabilities | 130,210 | 129,078 |
Commitments and contingencies (Note 18) | ||
Stockholders' (deficit) equity | ||
Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022 | ||
Common stock, $0.001 par value, 100,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,930 and 28,147 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 30 | 28 |
Additional paid-in-capital | 534,060 | 488,292 |
Accumulated deficit | (590,598) | (411,545) |
Total stockholders' (deficit) equity | (56,508) | 76,775 |
Total liabilities and stockholders' (deficit) equity | 73,702 | 205,853 |
Related Party | ||
Current liabilities | ||
Other current liabilities | 107 | 422 |
Nonrelated Party | ||
Current liabilities | ||
Other current liabilities | $ 346 | $ 404 |